Please try another search
CellSource Co., Ltd. engages in the regenerative medicine-related businesses in Japan. The company provides processing services to extract adipose-derived stem cells from patients’ adipose tissues, and to prepare platelet-rich plasma from patients’ blood; and offers support services for medical facilities providing regenerative medicine therapy, as well as manufacturing processed cells. It is also involved in the development and sale of Signalift series of anti-aging products, including a serum. The company was incorporated in 2015 and is headquartered in Tokyo, Japan.
Name | Age | Since | Title |
---|---|---|---|
Takashi Sawada | 67 | 2022 | Representative Director, President & CEO |
Masayuki Yamakawa | 60 | 2022 | Executive Chairman & MD |
Hirohiko Hanaki | 55 | 2017 | Executive Officer & Head of Medical Affairs Headquarters |
Norio Murakami | 77 | 2017 | Independent Outside Director |
Takeshi Amemiya | 62 | 2017 | Director |
Kumi Fujisawa | 57 | 2023 | Independent Outside Director |
Tsuneyasu Ozaki | 55 | 2019 | Independent Outside Director |
Masato Tsumamoto | 42 | 2024 | CXO, Chief Transformation Officer & Representative Director |
Futa Asada | 36 | 2023 | Executive Officer, Head of CPC Headquarters & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review